Pharmaceutical policies: effects of cap and co-payment on rational drug use (Q24242490)

Europe PubMed Central

title

Pharmaceutical policies: effects of cap and co-payment on rational drug use (English)

0 references

author

Astrid Austvoll-Dahlgren

1

0 references

Andrew D. Oxman

5

object named as

Andrew D Oxman

0 references

Gunn Elisabeth Vist

3

object named as

Gunn Elisabeth Vist

0 references

author name string

Morten Aaserud

2

0 references

Craig Ramsay

4

0 references

Heidrun Sturm

6

0 references

Jan Peter Kösters

7

0 references

Åsa Vernby

Cochrane Database of Systematic Reviews

8

0 references

publication date

23 January 2008

0 references

published in

0 references

cites work

Impact of a cost sharing drug insurance plan on drug utilization among individuals receiving social assistance

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Impact of increasing the re-supply interval on the seasonality of subsidised prescription use in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

The effect of incentive-based formularies on prescription-drug utilization and spending

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

The impact of implementing a more restrictive prescription limit on Medicaid recipients. Effects on cost, therapy, and out-of-pocket expenditures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Prescription drug utilization following patient co-payment changes in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Effect of a three-tier prescription copay on pharmaceutical and other medical utilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

The demand for prescription drugs as a function of cost-sharing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Some interim results from a controlled trial of cost sharing in health insurance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

A time-series analysis of the effect of increased copayments on the prescription of antidepressants, anxiolytics, and sedatives in Sweden from 1990 to 1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Effects of a limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Adverse events associated with prescription drug cost-sharing among poor and elderly persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Effect of a drug supply and cost sharing system on prescribing and utilization: a controlled trial from Nepal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Utilization of essential medications by vulnerable older people after a drug benefit cap: importance of mental disorders, chronic pain, and practice setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Health care policy evaluation using longitudinal insurance claims data: an application of the panel Tobit estimator

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Pharmaceutical cost-containment policy: experiences in Shanghai, China

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

The effect of increased prescription drug cost-sharing on medical care utilization and expenses of elderly health maintenance organization members

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

The effect of a patient charge and a prescription regulation on the use of antihypertension drugs in Limburg, The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Co-payments for prescription drugs and the demand for doctor visits--evidence from a natural experiment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Cost containment of pharmaceutical use in Iceland: the impact of liberalization and user charges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Changes in drug utilization following the outpatient prescription drug cost-sharing program--evidence from Taiwan's elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Pharmaceutical policies: effects on rational drug use

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

The case for a medicare drug coverage benefit: a critical review of the empirical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Interventions to improve antibiotic prescribing practices for hospital inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Fixed and flexible formularies as cost-control mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

European healthcare policies for controlling drug expenditure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Lessons from international experience in controlling pharmaceutical expenditure. I: Influencing patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Grading quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

An historical survey of UK government measures to control the NHS medicines expenditure from 1948 to 1996.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Mass media interventions: effects on health services utilisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

The use of prescription charges

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Prescription cost sharing: economic and health impacts, and implications for health policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

The effect of managed care on prescription drug costs and benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

The cost of prescription medicines to patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Economic impact of cost-containment strategies in third party programmes in the US (part I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Patient cost sharing for medical services: a review of the literature and implications for health care reform

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

The impact of cost-sharing on appropriate utilization and health status: a review of the literature on seniors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Impact of consumer fees on drug utilisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Experience of state drug benefit programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

The effect of cost sharing on the use of antibiotics in ambulatory care: Results from a population-based randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

Price elasticity and pharmaceutical selection: the influence of managed care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

7 January 2021

The effect of patient charges on the utilisation of prescription medicines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

7 January 2021

The effects of different kinds of user fees on prescribing quality in rural Nepal

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

7 January 2021

Impact of a cost-sharing drug insurance plan on drug utilization among older people

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

7 January 2021

Drug benefit plans under managed care: to what extent do older subscribers selecting less drug coverage put themselves at increased financial risk?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

7 January 2021

Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

7 January 2021

Pharmaceutical insurance and the demand for prescription pharmaceuticals in Västerbotten, Sweden

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

7 January 2021

Effects of changes in patient cost sharing and drug sample policies on prescription drug costs and utilization in a safety-net-provider setting.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

7 January 2021

The effects of different kinds of user fee on prescribing costs in rural Nepal

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

7 January 2021

Community financing of drug supplies in rural Nepal: evaluating a 'fee per item' drug scheme

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

7 January 2021

The effect of a Medicaid drug copayment program on the utilization and cost of prescription services

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

7 January 2021

Substitution between prescribed and over-the-counter medications.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

7 January 2021

A copayment increase for prescription drugs: the long-term and short-term effects on use and expenditures

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007017

7 January 2021